Abstract

Evidence of the prognostic value of pretreatment systemic immune-inflammation index (SII) after radical cystectomy (RC) for bladder cancer is limited. This study aims to assess the association between preoperative SII and prognosis after RC for bladder cancer. In this multicenter retrospective study, we calculated preoperative SII as well as the neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) in 237 patients who underwent RC for bladder cancer between March 2009 and March 2018. Patients were classified into high SII and low SII groups by using the optimal cutoff value (438 × 109/L) based on receiver operating characteristic curve analysis for cancer-specific death. We compared cancer-specific survival (CSS) and overall survival (OS) between the two groups. To evaluate the prognostic impact of preoperative SII, we also performed Cox proportional regression analyses for CSS and OS. Of 237 patients, 127 patients were classified into the high SII group and 110 patients into the low SII group. During the follow-up period, 70 patients died of bladder cancer (30%) and 21 patients died from other causes (9%). Patients with high SII had significantly lower rates of CSS and OS than those with low SII (p < 0.01 and p < 0.01, respectively). Multivariable Cox proportional hazard analysis showed that high SII was independently associated with poor CSS (p = 0.01) and poor OS (p < 0.01). In conclusion, high SII could be an independent significant predictor of poor prognosis after RC in patients with bladder cancer.

Highlights

  • We retrospectively reviewed the medical records of consecutive patients between March 2009 and March 2018 who underwent Radical cystectomy (RC) for bladder cancer at our three institutions

  • We investigated the impact of preoperative systemic immune-inflammation index (SII) on prognosis after RC in patients with bladder cancer

  • We focused on the preoperative peripheral blood count-associated factors because they were easy to use clinically and, as a result, showed the prognostic impact of SII in patients who underwent RC

Read more

Summary

Introduction

Bladder cancer is the ninth most common cancer worldwide [1]. Radical cystectomy (RC) remains the standard treatment for localized muscle-invasive bladder cancer, [2] and is indicated for patients with high-risk non-muscle invasive carcinoma or bacillus. Calmette–Guerin refractory carcinoma in situ [3,4]. Prognosis in patients who undergo RC is poor and their five-year overall survival (OS) rate after RC is around 50% [5]. Reliable biomarkers to predict prognosis in patients who undergo RC are desired, and several possible predictors have been examined

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.